Long-term Retinal Morphology and Functional Associations in Treated Neovascular Age-Related Macular Degeneration

被引:7
|
作者
Peto, Tunde [1 ]
Evans, Rebecca N. [2 ]
Reeves, Barnaby C. [2 ]
Harding, Simon [3 ,4 ,5 ]
Madhusudhan, Savita [3 ,4 ,5 ]
Lotery, Andrew [6 ]
Downes, Susan [7 ]
Balaskas, Konstantinos [8 ]
Bailey, Clare C. [9 ]
Foss, Alexander [10 ]
Ghanchi, Faruque [11 ]
Yang, Yit [12 ]
Phillips, Dawn [2 ]
Rogers, Chris A. [2 ]
Muldrew, Alyson [1 ]
Hamill, Barbra [1 ]
Chakravarthy, Usha [1 ]
机构
[1] Queens Univ Belfast, Royal Victoria Hosp, Belfast, North Ireland
[2] Univ Bristol, Bristol Trials Ctr, Bristol Med Sch, Bristol, Avon, England
[3] Univ Liverpool, Dept Eye & Vis Sci, Liverpool, Merseyside, England
[4] Liverpool Univ Hosp Natl Hlth Serv Fdn Trust, St Pauls Eye Unit, Liverpool, Merseyside, England
[5] Liverpool Hlth Partners, Liverpool, Merseyside, England
[6] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England
[7] Univ Hosp Natl Hlth Serv Trust, Oxford, England
[8] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, London, England
[9] Univ Hosp Bristol Natl Hlth Serv Fdn Trust, Dept Ophthalmol, Bristol, Avon, England
[10] Nottingham Univ Hosp, Dept Ophthalmol, Nottingham, England
[11] Bradford Royal Infirm, Dept Ophthalmol, Bradford, W Yorkshire, England
[12] New Cross Hosp, Dept Ophthalmol, Royal Wolverhampton Natl Hlth Serv Trust, Wolverhampton, England
来源
OPHTHALMOLOGY RETINA | 2022年 / 6卷 / 08期
关键词
VISUAL-ACUITY; GEOGRAPHIC ATROPHY; PREDICTOR; OUTCOMES; LAYER; VEGF;
D O I
10.1016/j.oret.2022.03.010
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To describe the frequency of long-term morphologic features and their relationships with visual function in participants who exited the Inhibition of VEGF in Age-Related Choroidal Neovascularisation (IVAN; ISRCTN92166560) trial. Design: Multicenter cohort study up to 7 years after enrollment. Participants: Patients enrolled in the IVAN trial, excluding participants who died or withdrew during the trial. Methods: Multimodal fundus images, best-corrected visual acuity (BCVA), and low-luminance visual acuity (LLVA) were obtained for a subset of 199 participants who attended a research visit. Clinical sites (n = 20) also provided all visual acuity and clinical information from usual care records for 532 participants and submitted the most recent color, OCT, and other fundus images for 468 participants to a reading center. Main Outcome Measures: Assessed the following from the most recent images: intralesional macular atrophy (ILMA) within the footprint of the neovascular lesion; hyperreflective material (HRM); intraretinal fluid (IRF); subretinal fluid (SRF); pigment epithelial detachment (PED); and disorganized retinal outer layers (DROLs). Cross-sectional relationships between morphologic features and BCVA/LLVA were estimated. Results: Intralesional macular atrophy was present in 31.8% of the study eyes at IVAN exit (mean follow-up, 1.96 years) and 89.5% at the most recent imaging visit (mean follow-up, 6.18 years). Hyperreflective material, IRF, SRF, PED, and DROLs were present in 78.8%, 47.7%, 7.6%, 94.5%, and 55% of the study eyes, respectively. In the subset with complete imaging data, in eyes without DROL, the BCVA was worst in the thinnest outer fovea tertile (thinnest minus middle and thickest tertiles, -19.7 and -19.5 letters, respectively), whereas in eyes with DROL, the BCVA was worst in the thickest (thinnest and middle tertiles minus thickest, 12.5 and 12.2, respectively). Regression models showed that the presence of ILMA and HRM was independently associated with BCVA (22 letters worse [95% confidence interval {CI},-11.2 to-32.8; P < 0.001] and 9.8 letters worse [95% CI,-0.1 to-19.4; P = 0.047], respectively). Subretinal fluid and foveal PED were associated with better BCVA (5.9 letters [95% CI, -7.9 to 19.7; P = 0.399] and 6.4 letters [95% CI, -1.1 to 14.0; P = 0.094], respectively). The model with LLVA was similar. A sensitivity analysis involving the entire eligible cohort yielded similar estimates. Conclusions: Macular atrophy and HRM were common after 7 years of follow-up and strongly associated with visual outcomes. Copyright (c) 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.
引用
收藏
页码:664 / 675
页数:12
相关论文
共 50 条
  • [1] Long-term Retinal Morphology and Functional Associations in Treated Neovascular Age-Related Macular Degeneration: Findings from the Inhibition of VEGF in Age-Related Choroidal Neovascularisation Trial
    Peto, Tunde
    Evans, Rebecca N.
    Reeves, Barnaby C.
    Harding, Simon
    Madhusudhan, Savita
    Lotery, Andrew
    Downes, Susan
    Balaskas, Konstantinos
    Bailey, Clare C.
    Foss, Alexander
    Ghanchi, Faruque
    Yang, Yit
    Phillips, Dawn
    Rogers, Chris A.
    Muldrew, Alyson
    Hamill, Barbra
    Chakravarthy, Usha
    OPHTHALMOLOGY, 2022, 129 (09) : 965 - 965
  • [2] Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration
    Matonti, Frederic
    Courjaret, Jean Christophe
    Hoffart, Louis
    Amouyal, Franck
    Denis, Daniele
    OPHTHALMOLOGY, 2013, 120 (09) : E68 - E69
  • [3] Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration
    Rasmussen, Annette
    Sander, Birgit
    CURRENT OPINION IN OPHTHALMOLOGY, 2014, 25 (03) : 158 - 163
  • [4] Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration Reply
    Silva, Rufino
    Axer-Siegel, Ruth
    Eldem, Bora
    Guymer, Robyn
    Kirchhof, Bernd
    Papp, Andras
    Seres, Andras
    Gekkieva, Margarita
    Nieweg, Annette
    Pilz, Stefan
    OPHTHALMOLOGY, 2013, 120 (09) : E69 - E69
  • [5] Long-Term Management of Neovascular Age-Related Macular Degeneration: To Suspend or Not to Suspend?
    Khurana, Rahul N.
    OPHTHALMOLOGY RETINA, 2019, 3 (08): : 621 - 622
  • [6] LONG-TERM EFFICACY OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Chang, Andrew A.
    Chew, Jamie
    Syed, Adil
    Joachim, Nichole
    Li, Haitao
    Broadhead, Geoffrey K.
    Zhu, Meidong
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 : 98 - 98
  • [7] Retinal Functional Changes Measured by Microperimetry in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab
    Cho, Han Joo
    Kim, Chul Gu
    Yoo, Su Jin
    Cho, Sung Won
    Lee, Dong Won
    Kim, Jong Woo
    Lee, Joon H.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (01) : 118 - 126
  • [8] Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab
    Damkondwar, Deepali R.
    Srinivasan, Ramyaa
    Raman, Rajiv
    Kulothungan, Vaitheeswaran
    Sharma, Tarun
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (12) : 4376 - 4382
  • [9] Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab
    Menke, Marcel N.
    Salam, Adzura
    Framme, Carsten
    Wolf, Sebastian
    OPHTHALMOLOGICA, 2013, 229 (03) : 168 - 172
  • [10] MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kuroda, Yoshimasa
    Yamashiro, Kenji
    Ooto, Sotaro
    Tamura, Hiroshi
    Oishi, Akio
    Nakanishi, Hideo
    Miyata, Manabu
    Hata, Masayuki
    Takahashi, Ayako
    Wakazono, Tomotaka
    Yoshimura, Nagahisa
    Tsujikawa, Akitaka
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (09): : 1743 - 1750